Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients

Clinical Implications of Hip Flexion in the Measurement of Spinal Bone Mineral Density

(2016) Shota Ikegami et al.   JOURNAL OF CLINICAL DENSITOMETRY

Bisphosphonate Pre-Treatment Diminishes the Therapeutic Benefits of Teriparatide in Japanese Osteoporotic Patients

(2016) Mikio Kamimura et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature

(2016) Jun Iwamoto   Clinical Interventions in Aging

Risks and Benefits of Bisphosphonate Therapies

(2015) Carlen Reyes et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

(2015) S. Ferrari et al.   OSTEOPOROSIS INTERNATIONAL

Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study

(2015) Yukio Nakamura et al.   BMC Endocrine Disorders

Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis

(2015) Ove Törring   Therapeutic Advances in Musculoskeletal Disease

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study

(2013) C. Roux et al.   BONE

Bisphosphonates: The first 40years

(2011) R. Graham G. Russell   BONE

Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase

(2010) Verena Stresing et al.   BONE

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide

(2010) A. Blumsohn et al.   OSTEOPOROSIS INTERNATIONAL

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH